Educational Administration: Theory and Practice
2024, 30(4), 11472-11485
ISSN: 2148-2403
https://kuey.net/

Review Article

Navigating The N-Nitrosamine Impurities Challenge: Comprehensive Strategies For Ensuring Paracetamol Purity Through Analytical Advances, Control Measures, And Emerging Mitigation Trends

Nishita Nagpure[1*], Harshal Raut[1], Deepak Askar[2], Neha Narange[1], Shrutika Bhurse[1], Dr. Rahul Kasliwal[3]

[1]M.Pharm Research Scholar, Department of Pharmaceutics, Priyadarshini J.L. College of Pharmacy, Nagpur, Maharashtra, India-440016
[2]Assistant Professor, Faculty of Pharmaceutical Sciences ICFAI University, Himachal Pradesh, India-174103
[3]Associate Professor, Department of Pharmaceutics, Priyadarshini J.L. College of Pharmacy, Nagpur, Maharashtra, India-440016

***Corresponding Author:** Nishita Nagpure
*Department of Pharmaceutics, Priyadarshini J.L. College of Pharmacy, Nagpur 440016, Maharashtra, India, Email: nishitanagpure4@gmail.com

Citation: Nishita Nagpure,, et.al (2024). Navigating The N-Nitrosamine Impurities Challenge: Comprehensive Strategies For Ensuring Paracetamol Purity Through Analytical Advances, Control Measures, And Emerging Mitigation Trends, *Educational Administration: Theory and Practice*, 30(4) 11472-11485
Doi: 10.53555/kuey.v30i4.10763

ARTICLE INFO

ABSTRACT

The presence of N-nitrosamine impurities in paracetamol, a widely utilized analgesic and antipyretic, has raised significant safety concerns over their potential carcinogenicity. This abstract explores the regulatory landscape surrounding these impurities, focusing on international collaboration among health authorities to establish comprehensive guidelines. N-nitrosamines can form during the manufacturing process when nitrous acid interacts with secondary amines, influenced by factors such as pH and temperature. Regulatory bodies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), have implemented stringent testing requirements to mitigate risks associated with these impurities. Key initiatives include revising pharmacopoeial standards and enhancing analytical methodologies, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS), for effective detection of nitrosamines in pharmaceutical products. The paper highlights the challenges faced by manufacturers in adhering to these guidelines, including communication gaps with regulatory authorities and the complexity of testing protocols. Furthermore, the impact of N-nitrosamine contamination extends beyond regulatory compliance, affecting public health through drug recalls and potential loss of patient trust in medications. Continuous monitoring and proactive risk management strategies are essential to ensure the safety of paracetamol and similar pharmaceuticals. In conclusion, addressing N-nitrosamine impurities requires a coordinated international effort to enhance safety measures, improve manufacturing practices, and maintain public confidence in pharmaceutical products. This collaboration is vital for safeguarding public health while ensuring the efficacy of essential medications like paracetamol.

Keywords: N-nitrosamines, paracetamol, carcinogenicity, regulatory guidelines, international collaboration, pharmaceutical safety, analytical methods, public health.

INTRODUCTION:

Acetaminophen, another name for paracetamol, is a common over-the-counter drug used to treat fever and pain. It was first synthesized in 1878 and introduced for limited medical use in 1883. In order to work, paracetamol blocks the brain's chemical messengers that indicate pain and interferes with those that control body temperature. When used as prescribed, it is usually safe for most individuals, but if taken in excess, it can seriously harm the liver. Adults should not take more over 3,000 milligrams (mg) per day. [1] There are several forms of paracetamol, such as liquid, tablets, and capsules. It is important to follow the directions on the label carefully and not to take more than the recommended dose.



Fig. 1. Paracetamol (Acetaminophen)

Widespread uses of Paracetamol:

• Pain Relief: Paracetamol is effective for minor pain to moderate pain, such as:
Headaches
Myalgia
Backache
Toothaches
Period pain
Post-surgical pain
Pain from the common cold or flu [2]

Drug profile of Paracetamol:

Table I:(Drug profile of paracetamol)

Feature	Description
Generic Name	Acetaminophen
Brand Names	Tylenol, Panadol, and many others
Drug Class	Antipyretic (which lowers fever), and analgesic (which relieves pain)
Mechanism of Action	Reduces heat and pain by blocking the production of prostaglandins in the CNS.
Uses	Minor to moderate pain (headache, myalgia, backache, toothache, etc.), fever
Dosage	Varies depending on age and condition. Follow the recommended dosage on the product label or as directed by a doctor.
Route of Administration	Oral (tablets, capsules, liquid)
Onset of Action	30 to 60 minutes
Duration of Action	4 to 6 hours
Side Effects	Generally well-tolerated; Nausea, vomiting, skin rashes, and liver damage (from an overdose) are among potential adverse effects.
Precautions	Do not exceed the recommended dosage. Avoid alcohol consumption while taking paracetamol. Consult a doctor if you have liver or kidney problems.
Pregnancy and Breastfeeding	Generally considered safe in recommended doses during pregnancy and breastfeeding, but consult a doctor for advice.
Overdose	Can cause serious liver damage; in severe cases, liver failure and death. Seek immediate medical attention if an overdose is suspected.
Interactions	May interact with other medications, including blood thinners and certain antibiotics. Consult a doctor or pharmacist about potential drug interactions. [1][3]

N – NITROSAMINE: A class of chemical compounds known as nitrosamines can be created when nitrite and secondary amines react. Certain nitrosamines have the potential to cause cancer since they are strong carcinogens.

Potential Carcinogenicity:

Mutagenic Effects

- Paracetamol does not cause gene mutations in bacteria or mammalian cells, but it has been shown to induce chromosomal damage under certain conditions. Studies indicate that paracetamol can lead to **chromosomal aberrations** and **DNA strand breaks** in mammalian cells, particularly at high concentrations or doses that induce significant toxicity.

The mechanisms proposed for these genotoxic effects include:

- **Inhibition of ribonucleotide reductase**: This enzyme is critical for DNA synthesis and repair.
- **Increased intracellular calcium levels**: Elevated Ca^{2+} can disrupt cellular functions and contribute to DNA damage.
- **Formation of N-acetyl-p-benzoquinone imine (NAPQI)**: This reactive metabolite can bind to DNA after glutathione depletion, leading to cellular injury.

While paracetamol exhibits genotoxic effects at high doses, such as those leading to liver toxicity, these effects are generally not observed at therapeutic levels. Research suggests that there is a **threshold for genotoxicity**, indicating that normal therapeutic use is unlikely to cause significant genetic damage. (4)

Animal Studies: Many nitrosamines have been shown to cause cancer in animals, including liver, lung, kidney, and stomach cancer. (5)

Human Exposure: While direct evidence of nitrosamine-induced cancer in humans is limited, exposure to certain nitrosamines has been linked to increased cancer risk.

Significance of reviewing N-nitrosamine impurities in paracetamol:

- **Carcinogenic Risk**: Based on research on animals, N-nitrosamines are categorized as likely carcinogenic for humans. Because prolonged exposure to levels over permissible limits may raise the risk of cancer, their presence in medications, such as paracetamol, must be closely monitored.(6)
- **Manufacturing Concerns**: The formation of nitrosamines can occur during the manufacturing process of paracetamol, particularly when nitrous acid interacts with amines present in the raw materials. This emphasizes the need for stringent quality control and risk assessment strategies in drug production to prevent contamination. (7)
- **Regulatory Compliance**: Regulatory bodies, such as the FDA and EDQM, have established guidelines for assessing and controlling nitrosamine impurities in pharmaceuticals. This includes setting acceptable daily intake limits and requiring manufacturers to implement measures to detect and mitigate these impurities. (8)
- **Public Health Assurance**: While low levels of nitrosamines are not expected to pose immediate health risks, ongoing surveillance and research are essential to ensure that medications like paracetamol remain safe for consumer use. The presence of these impurities could lead to recalls or modifications in manufacturing practices if unacceptable levels are detected. (6)
- **Consumer Confidence**: Transparency in addressing potential impurities helps maintain public trust in pharmaceutical products. Clear communication about the risks associated with nitrosamines and the measures taken to minimize them is vital for consumer safety and confidence. (6)

Chemistry and formation of N – Nitrosamines:

Nitrosamines are a class of organic compounds characterized by the general chemical structure **$R_2N–N=O$,** where R typically represents an alkyl or aryl group. This structure consists of a nitroso group (N=O) bonded to a secondary amine. (9)



(10)

Fig. 2 Some N – Nitrosamines

MECHANISM OF NITROSAMINE FORMATION:

The formation of nitrosamines primarily occurs through a chemical reaction known as nitrosation, which involves the interaction of secondary amines with nitrous acid (HNO_2) or nitrite salts under acidic conditions.

The key steps in this process include:

- Nitrosating Agents: Nitrous acid is typically generated from the protonation of nitrite ions (NO_2^-) in acidic environments. This acid is the active nitrosating agent that reacts with amines. (7)
- Role of Secondary Amines: Secondary amines are particularly prone to nitrosation because they possess hydrogen atoms attached to nitrogen, allowing them to react with the nitrous acid. The general reaction can be represented as follows:(11)

$$R_2NH+HONO \rightarrow R_2N\ NO+H_2OR_2NH+HONO \rightarrow R_2N\ NO+H_2O$$

In this reaction, the secondary amine (R_2NH) reacts with nitrous acid (HONO) to form a nitrosamine (R_2N-NO) and water. (12)

- **Environmental Factors:** The formation of nitrosamines can be influenced by various environmental conditions, including:

1. **pH Levels:** Acidic conditions favor the formation of nitrous acid from nitrite, enhancing the likelihood of nitrosamine formation.
2. **Temperature:** Higher temperatures can accelerate chemical reactions, potentially increasing the rate at which nitrosamines form.
3. **Presence of Other Compounds:** Certain solvents and reagents may degrade under specific conditions, releasing secondary amines that can subsequently react with HNO_2 to form nitrosamines.

- **Zwitterionic Resonance Structures:** Some nitrosamines can exist in zwitterionic forms, which may influence their stability and reactivity. This resonance stabilization can affect how these compounds behave in biological systems and their potential carcinogenicity. (13)

THE POTENTIAL SOURCES OF NITROSAMINE IMPURITIES IN MANUFACTURING:

1. **Vendor-Sourced Raw Materials**:

- **Impurities in Raw Materials**: When nitrosamines or their precursors are existing in raw materials purchased from vendors, nitrosamines may be introduced. For instance, starting materials such as sodium azide or nitrate-containing compounds may contain sodium nitrite, a recognized nitrosating agent, as an impurity. In acidic environments, this chemical can react with amines to generate nitrosamines.
- **Cross-Contamination**: Cross-contamination at manufacturing facilities where nitrosamine impurities may transfer from other processes could endanger API starting materials and intermediates.(7)

2. **Solvents and Reagents**:

- **Fresh Solvents**: Certain solvents (e.g., ortho-xylene, toluene) may carry over impurities during transfer between storage vessels, leading to the introduction of nitrosamines into the manufacturing process.
- **Recovered Solvents**: Recovered solvents that contain residual amines can pose a risk if these solvents are not adequately purified. The recovery process may involve quenching steps will cause the formation of nitrosamines. (7)(14)

3. **Quenching Processes**:

- When nitrous acid is introduced during quenching phases to break down leftover azides directly in the main reaction mixture, there is a considerable chance that nitrosamine will occur. This enables leftover amines from raw materials to come into contact with nitrous acid, which could result in the creation of nitrosamines if proper removal or purifying procedures are not carried out.(7)

4. **Lack of Process Optimization**:

- Inadequate control over reaction environments such as temperature and pH can facilitate the formation of nitrosamines. Manufacturers need to optimize these conditions to minimize the risk during synthesis.(15)

5. **Synthetic Pathways**:

- The choice of synthetic route for paracetamol can influence the risk of nitrosamine formation. For instance, processes that utilize chlorobenzene as a starting material have been associated with higher risks compared to those using phenol. (16)

6. **Recycling and Outsourcing**:

- The recycling of materials and solvents often involves third-party processors who may not implement sufficient controls. This can lead to cross-contamination with nitrosamines or their precursors if equipment is not adequately cleaned between uses.(14)

7. **Environmental Factors**:
- Conditions such as pH and temperature during manufacturing can affect the stability and reactivity of both amines and nitrous acid, potentially leading to increased nitrosamine formation under certain circumstances. [7,14]

REGULATORY CONCERNS AND GUIDELINES:

1. **FDA Guidance**:
- "Control of Nitrosamine Impurities in Human Drugs," a guidance published by the FDA, describes how manufacturers can identify and stop excessive amounts of nitrosamine impurities in active pharmaceutical ingredients (APIs) and pharmaceutical products. This entails reporting modifications to reduce the presence of nitrosamines, performing risk assessments, and performing confirmatory tests.[7]
- Manufacturers are responsible for understanding their processes and implementing suitable detection methods for nitrosamine impurities. The FDA emphasizes that if drugs contain nitrosamines above acceptable limits, they should be recalled or not released for distribution.[6]

2. **Health Canada Guidelines**:
- Health Canada has provided guidance that includes timelines for completing risk assessments, confirmatory testing, and market authorization variations related to nitrosamine impurities. For chemically synthesized APIs, risk assessments were expected by March 31, 2021, with confirmatory testing by October 1, 2022, and changes to market authorization by August 1, 2025. [17]

3. **European Medicines Agency (EMA)**:
- The EMA has also updated its guidelines regarding nitrosamine impurities, focusing on the assessment of Nitrosamine Drug Substance Related Impurities (NDSRIs). This reflects a shift towards more comprehensive risk evaluations concerning potential nitrosamine formation in human medicinal products. [18]

1. **Global Collaboration:**
- To identify N-nitrosamine contaminants, regulatory agencies including the US FDA, Health Canada, and others have created a number of testing techniques. These include sophisticated methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC/MS).
- The ZaZiBoNa initiative, which involves several National Regulatory Authorities (NRAs) in Southern Africa, highlighted the importance of collaborative reliance on safety reviews. This approach aims to enhance communication and streamline processes for assessing N-nitrosamine impurities across different jurisdictions. (6)

ACCEPTABLE DAILY INTAKE (ADI) LIMITS FOR N-NITROSAMINES IN HARMACEUTICALS:

Table 2.(Acceptable Daily Intake)

Nitrosamine	FDA Acceptable Intake Limit (ng/day)	EMA Acceptable Intake Limit (ng/day)	Comments
N-Nitrosodimethylamine (NDMA)	96	96	Commonly referenced limit for NDMA across both agencies. [19]
N-Nitrosodiethylamine (NDEA)	26.5	26.5	Consistent limit for NDEA as per FDA and EMA guidelines. [20]
N-Nitrosomethylbenzylamine (NMBA)	96	Not specified	Limit established based on carcinogenicity risk assessment. [21]
N-Nitrosomethylpyrrolidine (NMPA)	26.5	Not specified	Similar limit as NDEA, reflecting its risk profile.
N-Nitrosopiperidine (NIPEA)	26.5	Not specified	Consistent with other secondary amines.
Total Nitrosamines	0.03 ppm (equivalent to 26.5 ng/day for MDD < 880 mg)	Not specified	Recommended limit for total nitrosamines in drug product. [22]

Unless there is a compelling reason to do otherwise, the FDA advises that if a medication product includes more than one nitrosamine, the total limit should not be higher than the permissible intake limit for the most

potent nitrosamine impurity. The EMA has similar approaches but may not specify limits for all nitrosamines, relying on risk assessments and toxicological data. Both agencies emphasize the importance of risk assessments and adherence to established limits to ensure patient safety. [23]

Impact of N-Nitrosamines Detections on Drug Recalls and Regulatory Actions:

1. **Significant Number of Recalls**:
- Over **1,400 product lots** have been recalled due to the presence of carcinogenic N-nitrosamine impurities exceeding acceptable limits, particularly affecting medications such as valsartan, irbesartan, losartan, metformin, ranitidine, and nizatidine. [24]

2. **Regulatory Actions**:
- Regulatory bodies like the **FDA** and **EMA** have issued guidance documents instructing manufacturers to control nitrosamine levels in drug products. This includes conducting risk assessments and implementing testing protocols to ensure obedience with established acceptable daily intake (ADI) limits. [24]

3. **Patient Safety Concerns**:
- The presence of nitrosamines, which are linked to an increased risk of cancer, has raised serious safety concerns. As a result, drugs found to contain these impurities at unacceptable levels are subject to immediate recalls to protect public health. [25]

4. **Impact on Drug Adherence**:
- Studies indicate that recalls can disrupt patient adherence to prescribed medications. For example, after the initial recalls in July 2018 for valsartan-containing products, there was a significant decline in its prescriptions, with many patients switching to alternative angiotensin receptor blockers (ARBs). [26]

5. **Market Dynamics**:
- The recalls have led to shifts in market dynamics, with increased prescriptions for alternative medications such as candesartan following the recalls of valsartan and other ARBs. This reflects a rapid response from both healthcare providers and patients seeking safe alternatives. [26]

6. **Ongoing Monitoring and Future Risks**:
- The ongoing detection of nitrosamines continues to pose challenges for manufacturers and regulators alike. New detections lead to further recalls and necessitate updates in regulatory guidelines, emphasizing the need for continuous monitoring and stringent quality control measures in pharmaceutical manufacturing. [27]

7. **Industry Response**:
- The pharmaceutical industry is now more vigilant regarding quality control practices and is investing in better testing methods to prevent nitrosamine formation during drug production. This proactive approach aims to minimize future recalls and ensure compliance with safety regulations. [28]

ANALYTICAL METHODS FOR N-NITROSAMINE DETECTIONS:

Because nitrosamines are potentially carcinogenic, it is crucial to identify and measure them in medications. For this, a number of analytical methods are frequently used, most notably Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS/MS). An explanation of these methods and how they are used in nitrosamine analysis is provided below.

Commonly Used Analytical Techniques

Table3:(commonly used analytical techniques)

Technique	Description	Applications
LC-MS/MS	Liquid Chromatography coupled with Tandem Mass Spectrometry (LC-MS/MS) is a highly sensitive method that allows for the separation of nitrosamines from complex matrices followed by their identification and quantification. The technique uses multiple reaction monitoring (MRM) to enhance sensitivity and specificity.	Widely used for quantifying nitrosamines such as NDMA, NDEA, and NMBA in pharmaceuticals like sartans and metformin.[29]
GC-MS	Gas Chromatography coupled with Mass Spectrometry (GC-MS) is another effective method for analyzing volatile as well as semi-volatile nitrosamines. It involves the vaporization of samples followed by separation in a chromatographic column and detection via mass spectrometry.	Commonly used for detecting nitrosamines in various drug formulations, including extended-release formulations.[30]
GC-MS/MS	An advanced version of GC-MS that utilizes tandem mass spectrometry to improve detection limits and specificity. This method is particularly useful for analyzing low levels of nitrosamines in complex matrices.	Employed in the quantification of nitrosamines in pharmaceuticals where high sensitivity is required.[30]

Headspace GC-MS	This technique involves sampling the vapor above a solid or liquid sample, which is then analyzed by gas chromatography. It is particularly useful for volatile compounds like nitrosamines, allowing for efficient extraction without extensive sample preparation.	Effective in detecting volatile nitrosamines in pharmaceutical products.[31]

Sensitivity and Specificity of LC-MS/MS

1. Sensitivity:

- **Detection Limits**: LC-MS/MS methods have demonstrated detection limits as low as **5 ppb** (parts per billion) using Atmospheric Pressure Chemical Ionization (APCI) and **10 ppb** using Heated Electrospray Ionization (HESI) for quantifying nitrosamines in pharmaceutical products such as metformin. This high sensitivity is essential for meeting regulatory requirements, which often stipulate that nitrosamines must be detected at very low concentrations.[32]
- **Quantification of Multiple Nitrosamines**: Advanced LC-MS/MS methods can simultaneously quantify multiple nitrosamines (e.g., NDMA, NDEA, NMBA) in a single run, enhancing throughput and efficiency in testing laboratories.[33]

2. Specificity:

- **Robustness Against Matrix Effects**: LC-MS/MS provides high specificity due to the ability to differentiate between closely related chemical structures, which is vital given that nitrosamines can be structurally similar to other compounds present in pharmaceuticals. The use of multiple reaction monitoring (MRM) enhances specificity by focusing on specific ion transitions associated with each nitrosamine.[34]
- **Method Validation**: Studies indicate that validated LC-MS/MS methods exhibit high accuracy and precision, making them suitable for routine screening of nitrosamine impurities in various drug formulations.[35]

Sensitivity and Specificity of GC-MS/MS

1. Sensitivity:

Detection Capabilities: GC-MS/MS is also capable of detecting low levels of nitrosamines; however, it may not achieve the same sensitivity as LC-MS/MS for certain non-volatile or thermally unstable nitrosamines without derivatization. The sensitivity can vary depending on the specific nitrosamine being analyzed and the conditions used during analysis.[36]

Pre-column Derivatization: To enhance sensitivity for non-volatile nitrosamines, derivatization techniques are often employed prior to GC analysis, allowing for improved detection limits.

Several reagents have been employed for pre-column derivatization of nitrosamines:

- **NBD-Cl (4-chloro-7-nitrobenzofurazane)**: This reagent has shown superior chromatographic signals for dimethylamine (DMA) and diethylamine (DEA), making it a preferred choice for sensitive analyses.[37]
- **Dansyl Chloride**: While commonly used, it has limitations due to potential contamination issues that can affect reproducibility. It is less effective for certain nitrosamines compared to other reagents.
- **Fmoc-Cl**: Another alternative that has been explored but may not provide the same level of sensitivity as NBD-Cl or other reagents.[38]

2. Specificity:

- **Separation Efficiency**: GC-MS/MS provides excellent separation capabilities due to the inherent nature of gas chromatography, which can effectively resolve complex mixtures. This allows for the accurate identification of nitrosamines even in the presence of other volatile compounds.
- **Mass Spectrometric Identification**: The mass spectrometry component provides high specificity through the identification of unique mass-to-charge ratios (m/z) for each nitrosamine, facilitating accurate quantification even at low concentrations.[39]

RISK ASSESSMENT PROCESS FOR NITROSAMINE IMPURITIES:

1. Identification of Potential Sources:

- The first step involves identifying potential sources of nitrosamines during the manufacturing process, including raw materials, solvents, reagents, and degradation products. Manufacturers must review their processes to pinpoint any pathways that could lead to nitrosamine formation or contamination during production and storage.[40][7]

2. **Exposure Assessment**:
- **Determining Levels of Nitrosamines**: Assess the concentration of nitrosamines in the drug product and estimate the potential exposure to patients based on typical dosing regimens. This includes evaluating both the API and the final drug product.(7)
- **Patient Population Consideration**: Consider the demographics of the patient population (e.g., age, health status) that may be exposed to the drug, as this can influence risk levels.(7)

3. **Toxicity Assessment**:
- **Toxicological Data Review**: Evaluate existing toxicological data for the identified nitrosamines to understand their carcinogenic potential and other health risks. This includes reviewing studies that categorize nitrosamines based on their mutagenic properties and potential to cause cancer.(41)(21)
- **Ames Test and Other Assays**: To find out if the nitrosamine is a known mutagen, do particular tests like the Ames test. Acceptable limits for each nitrosamine in APIs and pharmaceutical products can be determined using this data. Using particular bacterial strains (usually Salmonella typhimurium and Escherichia coli) that contain mutations that prevent them from producing vital amino acids like histidine or tryptophan, the Ames test assesses mutagenicity. These bacteria may experience reversal mutations in response to a mutagen, which would enable them to proliferate on media devoid of these amino acids. The quantity of colonies that proliferate reveals the tested substance's capacity to cause mutations.(41)

Other assays are employed to assess the toxicity of nitrosamines:

Comet Assay: This assay measures DNA damage in individual cells and is useful for assessing genotoxicity. It can complement the findings from the Ames test by providing additional insights into DNA strand breaks induced by nitrosamines.

Micronucleus Assay: This assay evaluates chromosomal damage by measuring micronuclei formation in erythrocytes. It is another method to assess genotoxic effects and complements bacterial assays.

Cell Culture Models: Human cell lines can be used to evaluate cytotoxicity and genotoxicity, providing a more relevant biological context for human exposure scenarios.(41)

4. **Margin of Exposure (MoE) Calculation**:
- Calculate the Margin of Exposure by comparing the estimated exposure levels to established acceptable intake limits for each nitrosamine. A higher margin indicates a lower risk. The FDA recommends that if the MoE is less than 100,000 for combined nitrosamines, further action may be necessary.
- The calculation typically follows this formula:

$$\text{MoE} = \frac{\text{No Observed Adverse Effect Level (NOAEL)}}{\text{Estimated Human Exposure}}$$ (41)(21)

5. **Risk Characterization**:
- Summarize the findings from exposure and toxicity assessments to characterize the overall risk associated with nitrosamine impurities in the drug product. This characterization should include an evaluation of whether identified risks exceed acceptable limits and what actions may be necessary.(42)

6. **Confirmatory Testing**:
- If risks are identified, manufacturers must conduct confirmatory testing using validated analytical techniques to enumerate nitrosamine levels in batches of drug products. This step ensures that any detected levels are accurately measured against regulatory limits.(42)(21)

7. **Implementation of Control Approaches**:
- Based on the results of the risk assessment and confirmatory testing, manufacturers must impose appropriate control approaches to mitigate risks. This may involve reformulating products, enhancing quality control measures, or changing suppliers for raw materials.(41)

8. **Documentation and Continuous Monitoring**:
- Maintain comprehensive documentation of all risk assessments, testing results, and control strategies implemented. Regularly review and update these assessments as new data becomes available or as manufacturing processes change.(21)

STRATEGIES FOR MITIGATING NITROSAMINE FORMATION:

1. **Process Optimization**:
- **Temperature Control**: Maintaining lower temperatures during synthesis can reduce the likelihood of nitrosamine formation, as many nitrosamines are formed under elevated temperatures. Processes should be designed to minimize heat exposure during critical reaction steps.

- **pH Adjustment**: The reaction environment's pH plays a crucial role in nitrosamine formation. Increasing the pH (making it more basic) can inhibit the nitrosation reaction, as acidic conditions tend to promote nitrosamine formation. Incorporating pH modifiers, such as sodium carbonate, can help maintain a less acidic environment during production.
- **Minimizing Reaction Time**: Shortening the duration of reactions where nitrosating agents are present can also reduce the potential for nitrosamine formation. Process engineers should evaluate and optimize reaction times to limit exposure.[43]

2. **Raw Materials Selection**:

- **Quality of Raw Materials**: Choosing high-quality raw materials with low levels of nitrites and nitrates is essential. Suppliers should provide detailed information about the chemical composition of raw materials to ensure they do not contain precursors that could lead to nitrosamine formation.[43]
- **Alternative Starting Materials**: Utilizing alternative starting materials that do not contain secondary amines or other reactive groups can help prevent nitrosamine formation. For instance, using phenol instead of chlorobenzene in paracetamol synthesis has been shown to eliminate certain impurities.
- **Supplier Qualification**: Conducting thorough assessments of suppliers to ensure that their raw materials meet stringent quality standards can help mitigate risks associated with nitrosamines.[44]

3. **Control of Reaction Conditions**:

- **Avoiding Nitrosating Agents**: Careful management of reagents is crucial; avoiding the use of nitrous acid or other known nitrosating agents in reactions involving secondary amines can significantly reduce the risk of forming nitrosamines.[43]
- **Incorporation of Antioxidants**: Adding antioxidants, such as vitamin C or vitamin E, to formulations can inhibit the formation of nitrosamines by reacting with potential nitrosating agents before they can interact with amines. Studies have shown that antioxidants can effectively mitigate nitrosamine formation when included in appropriate concentrations.

4. **Stability Testing Under Various Conditions**: Conducting stability studies under different environmental conditions (e.g., humidity, temperature) can help identify optimal storage and handling practices that minimize degradation and subsequent nitrosamine formation during shelf life.[45]
5. **Implementation of Additional Purification Steps**:

- Incorporating additional purification steps in the manufacturing process can help remove any formed nitrosamines before final product formulation. Techniques such as chromatography or recrystallization may be employed to achieve this.[43]

6. **Regulatory Compliance and Risk Assessment**:

- Following guidelines from regulatory agencies like the FDA and EMA regarding risk assessment and mitigation strategies is essential. Manufacturers should regularly review their processes and implement changes based on emerging data about nitrosamines.[22]

CASE STUDIES OF NITROSAMINE DETECTIONS IN PARACETAMOL PRODUCTS, INCLUDING REGULATORY RESPONSES AND RECALLS:

Case Study 1: Swissmedic's Findings on Paracetamol

Background

In September 2023, Swissmedic reported the identification of nitrosamines related to paracetamol synthesis. Among the findings, **15 nitrosamines** derived from paracetamol synthetic impurities were identified, with one specific nitrosamine linked directly to paracetamol itself.

Regulatory Response

- **Mandatory Testing**: Swissmedic mandated that manufacturers of active pharmaceutical ingredients (APIs) containing secondary amines perform systematic testing for nitrosamines by September 30, 2024. This includes routine testing of drug products if nitrosamine levels exceed specified thresholds.
- **Risk Assessment Protocols**: The agency emphasized a risk-based approach focusing on nitrosamines with high toxicological potential, requiring manufacturers to categorize their APIs and notify Swissmedic about those falling into higher risk categories by January 31, 2024.[46]

Case Study 2: Detection of N-nitrosamines in Paracetamol Products

Background

In August 2020, the Medicines Evaluation Board (MEB) in the Netherlands conducted an investigation following reports of para-chloroaniline (PCA) contamination in paracetamol produced by Chinese

manufacturers. Although PCA is not a nitrosamine, the investigation highlighted concerns regarding impurities in paracetamol.

Regulatory Response

- **Batch Testing**: The MEB tested multiple batches of paracetamol from different manufacturers to ensure compliance with safety standards. The results indicated that PCA levels did not exceed established safety limits, allowing continued use of paracetamol in the Netherlands.[47]

Case Study 3: Valsartan and Broader Implications for Pharmaceuticals

Background

While not directly related to paracetamol, the recall of valsartan products due to N-nitrosodimethylamine (NDMA) contamination in 2018 raised awareness about nitrosamine impurities across various pharmaceuticals, including over-the-counter medications like paracetamol.

Regulatory Response

- **Increased Scrutiny**: Following the valsartan recalls, regulatory agencies globally increased scrutiny on all medications for nitrosamine impurities. This included issuing guidance documents for manufacturers regarding risk assessments and testing protocols.
- **Voluntary Recalls**: Many companies initiated voluntary recalls of products suspected to contain unacceptable levels of nitrosamines, leading to heightened consumer awareness and regulatory vigilance across all pharmaceutical products.[48][49]

Recent Research and Developments on N-Nitrosamine Control and Analysis:

1. FDA Guidance Updates:

- In September 2024, the FDA published a significant update to its guidance titled "Control of Nitrosamine Impurities in Human Drugs." This revision (Revision 2) introduces a differentiation between smaller nitrosamines (common impurities) and bigger, more complex nitrosamine drug substance-related impurities (NDSRIs).[50]
- The updated guidance emphasizes a holistic approach to controlling nitrosamines, integrating the Recommended Acceptable Intake Limits (RAIL) and the Carcinogenic Potency Categorization Approach (CPCA). It also specifies that if nitrosamine levels exceed 10% of the proposed acceptable intake, individually API product batch must be tested at release and stability dates.[22][50]

2. Health Canada Initiatives:

- Health Canada has been proactive in updating its guidelines on nitrosamine impurities. In June 2024, they recalled several lots of PMS-Duloxetine and Sanis-Duloxetine due to nitrosamine contamination.
- The agency has also revised its Acceptable Intake (AI) limits for various nitrosamines, incorporating new data derived from CPCA assessments. As of December 2024, Health Canada added ten new nitrosamines to its established AI limits and revised limits for existing ones based on structure-activity relationship assessments.[17]

3. Analytical Techniques:

- Advances in analytical methods for detecting nitrosamines have been a focal point of recent research. Techniques such as LC-MS/MS and GC-MS/MS continue to be refined for better sensitivity and specificity in quantifying nitrosamines in pharmaceutical products. The development of pre-column derivatization procedures enhances the finding capabilities for non-volatile nitrosamines.[7][50]
- Research has also explored the Enhanced Ames Test (EAT) conditions and other methodologies for assessing the carcinogenic potential of nitrosamines, which can influence regulatory decisions regarding acceptable limits.[17]

4. Industry Response and Risk Mitigation:

- Pharmaceutical companies are increasingly adopting risk-based approaches to assess and manage nitrosamine impurities. This includes conducting thorough risk assessments during drug development and manufacturing processes to identify potential sources of contamination.
- Companies are implementing stricter quality control measures, including enhanced testing protocols and supplier audits to ensure raw materials are free from nitrosamine precursors.[22][50]

5. International Collaboration:

- There is a growing trend towards harmonization of guidelines across regulatory agencies globally. The FDA's recent updates align more closely with practices adopted by the European Medicines Agency (EMA) and Health Canada, facilitating a more unified approach to managing nitrosamine risks in pharmaceuticals.[17][50]

CONCLUSIONS:

Based on research on animals, N-nitrosamines are categorized as likely carcinogenic for humans. Prolonged exposure to these contaminants may raise the risk of cancer, thus medications, especially paracetamol, must be closely monitored. Particularly in acidic environments, secondary amines and nitrous acid or nitrite salts undergo a nitrosation process to produce nitrosamines. Temperature and pH levels are examples of environmental variables that can affect this process. Vendor-sourced raw materials, solvents, quenching procedures, and insufficient process optimization are all possible causes of nitrosamine impurities in the production of paracetamol. Another major worry is cross-contamination during manufacture. The FDA and EMA, among other regulatory agencies, have set standards for evaluating and managing nitrosamine contaminants in medications. These guidelines include setting acceptable daily intake (ADI) limits and requiring manufacturers to implement detection and mitigation measures. The detection of nitrosamines has led to significant drug recalls, with over 1,400 product lots affected across various medications. This has implications for patient safety and adherence to prescribed treatments. Advanced analytical methods like LC-MS/MS and GC-MS are critical for detecting and quantifying nitrosamines in pharmaceutical products. These techniques provide high sensitivity and specificity, essential for regulatory compliance.

Continuous surveillance and research are necessary to ensure that medications like paracetamol remain safe for consumer use. The presence of nitrosamine impurities could lead to recalls or changes in manufacturing practices if unacceptable levels are detected. There is a pressing need for stringent quality control measures in the manufacturing processes of pharmaceuticals to prevent nitrosamine formation. This includes optimizing reaction conditions, selecting appropriate raw materials, and implementing effective purification steps. Manufacturers must adhere to updated regulatory guidelines regarding nitrosamine impurities, which may require additional testing and reporting protocols. This compliance is crucial for maintaining market authorization and ensuring patient safety. Transparency in addressing potential impurities helps maintain public trust in pharmaceutical products. Clear communication about the risks associated with nitrosamines and the measures taken to minimize them is vital for consumer safety.

Effective quality control measures are essential to prevent the introduction of nitrosamine impurities during the manufacturing process. This includes stringent monitoring of raw materials, solvents, and reagents to ensure they are free from nitrosamines or their precursors. Implementing rigorous quality control protocols allows manufacturers to optimize production processes, including controlling reaction conditions such as temperature and pH. This minimizes the risk of nitrosamine formation, ensuring that paracetamol products remain safe for consumer use. Robust quality control ensures compliance with these regulations, preventing potential recalls and legal issues. Continuous monitoring enables early detection of impurities, allowing for prompt corrective actions to mitigate risks. Continuous vigilance in monitoring nitrosamine levels in paracetamol products is crucial for maintaining public health. Regular testing and reviews of manufacturing processes help identify potential contamination sources before they pose a risk to consumers. The pharmaceutical landscape is dynamic, with new risks emerging over time. Continuous vigilance allows manufacturers to adapt their quality control measures in response to new findings related to nitrosamines or changes in regulatory standards. Transparency in addressing potential impurities through robust quality control and continuous monitoring fosters consumer trust in pharmaceutical products. Clear communication about safety measures taken to minimize nitrosamine risks is vital for maintaining public confidence. The presence of nitrosamines can lead to significant recalls, affecting market dynamics and patient adherence to medications. Continuous vigilance helps prevent such scenarios by ensuring that products meet safety standards before reaching consumers. Future Research Directions-Ongoing research into the mechanisms of nitrosamine formation and improved analytical methods will be essential for enhancing detection capabilities and understanding the long-term implications of exposure to these compounds.

CONFLICT OF INTERESTS:

The authors have no conflicts of interest regarding this investigation.

ACKNOWLEDGMENTS:

No acknowledgments.

REFERENCES:

1) Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temperature (Austin). 2021 Mar 16;8(4):351-371. doi: 10.1080/23328940.2021.1886392.
2) "Paracetamol." NHS Inform, NHS, 13 Aug. 2024, www.nhsinform.scot/tests-and-treatments/medicines-and-medical-aids/types-of-medicine/paracetamol. Accessed 21 Jan. 2025.
4) "Public Consultation on Nitrosamines in Food: Draft Opinion Explained." European Food Safety Authority, 21 Jan. 2025, www.efsa.europa.eu/en/news/public-consultation-nitrosamines-food-draft-opinion-explained. Accessed 21 Jan. 2025.
5) Song P, Wu L, Guan W. Dietary Nitrates, Nitrites, and Nitrosamines Intake and the Risk of Gastric Cancer: A Meta-Analysis. Nutrients. 2015 Dec 1;7(12):9872-95. doi: 10.3390/nu7125505. PMID: 26633477; PMCID: PMC4690057.
6) "Drug Safety and Availability." U.S. Food and Drug Administration, 21 Jan. 2025, www.fda.gov/drugs/drug-safety-and-availability. Accessed 21 Jan. 2025.
7) "Control of Nitrosamine Impurities in Human Drugs." U.S. Food and Drug Administration, 21 Jan. 2025, www.fda.gov/media/141720/download. Accessed 21 Jan. 2025.
8) "EDQM." European Directorate for the Quality of Medicines & HealthCare, Council of Europe, 21 Jan. 2025, www.edqm.eu/en/edqm. Accessed 21 Jan. 2025.
9) "Search Results for Nitrosamine." Antteknik, 21 Jan. 2025, www.antteknik.com/en/search/?q=nitrosamine. Accessed 21 Jan. 2025.
10) "An Organic Chemist's Guide to N-Nitrosamines: Their Structure, Reactivity, and Role as Contaminants." United States Pharmacopeia, 21 Jan. 2025, nitrosamines.usp.org/t/an-organic-guide-to-n-nitrosamines-structure-reactivity-and-role-as-contaminants/1817. Accessed 21 Jan. 2025.
11) "Amine." Wikipedia, The Free Encyclopedia, 21 Jan. 2025, en.wikipedia.org/wiki/Amine. Accessed 21 Jan. 2025.
12) Snodin, David J., et al. "Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency." *Current Drug Safety*, vol. XX, no. XX, 2024, pp. XX-XX. PubMed, https://pubmed.ncbi.nlm.nih.gov/38316048/. Accessed 21 Jan. 2025.
13) National Center for Biotechnology Information. "PubChem Compound Summary for CID 37183, Nitrosamines" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/nitrous-amide. Accessed 21 January, 2025.
14) "Information Note on Nitrosamine Impurities." World Health Organization, 20 Nov. 2019, www.who.int/news/item/20-11-2019-information-note-nitrosamine-impurities. Accessed 21 Jan. 2025.
15) "Access to Swissmedic eGov Service via the CH-LOGIN Procedure." Swissmedic, 21 Jan. 2025, www.swissmedic.ch/swissmedic/en/home/services/egov-portal.html. Accessed 21 Jan. 2025.
16) "Report on Paracetamol and PCA." Medicines Evaluation Board, 26 Aug. 2020, www.english.cbg-meb.nl/binaries/medicines-evaluation-board/documenten/reports/2020/08/26/report-on-paracetamol-and-pca/200826+Rapportage+paracetamol+en+PCA+EN.pdf. Accessed 21 Jan. 2025.
17) "Drug Product Database." Health Canada, Government of Canada, 21 Jan. 2025, www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed 21 Jan. 2025.
18) QbD Group. "Nitrosamine Impurities in Medicinal Products: Risks and Regulatory Insights." *QbD Group*, 21 Jan. 2025, https://qbdgroup.com/en/blog/nitrosamine-impurities-in-medicinal-products-risks-and-regulatory-insights/.
19) FDA. "CDER Nitrosamine Impurity Acceptable Intake Limits." U.S. Food and Drug Administration, 4 Aug. 2023, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits. Accessed 21 Jan. 2025.
20) Kymos. "FDA New Guidance: NDSRIs Recommended Acceptable Intake Limits." Kymos, 21 Jan. 2025, https://kymos.com/news/fda-guidance-ndsri-recommended-ai-limits/
21) Food and Drug Administration. "Control of Nitrosamine Impurities in Human Drugs." FDA, September 2024, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs.
22) Food and Drug Administration. "Information About Nitrosamine Impurities in Medications." FDA, 4 Sept. 2024, https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities- medications.
23) European Medicines Agency. "Nitrosamine Impurities." EMA, 21 Jan. 2025, https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/referral-procedures-human-medicines/nitrosamine-impurities.

24) Bharate SS. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. J Med Chem. 2021 Mar 25;64(6):2923-2936. doi: 10.1021/acs.jmedchem.0c02120. Epub 2021 Mar 11. PMID: 33706513.
25) Painginkar, Tanvi, Tejas Sanjay Sonawane, Ruchir Bavadia, Sg Vasantharaju, Muddukrishna Badamane Sathyanarayana, and Gundawar Ravi. "Navigating Nitrosamines: Origin, Detecting, Analysing and Regulating Impurities in Pharmaceuticals." *International Journal of Applied Pharmaceutics*, vol. 16, no. 5, 2024, pp. 1–11. https://doi.org/10.22159/ijap.2024v16i5.51376.
26) Hedenmalm, Karin, Chantal Quinten, Xavier Kurz, Marie Bradley, Hana Lee, and Efe Eworuke. "A Collaborative Study of the Impact of N-Nitrosamines Presence and ARB Recall on ARB Utilization – Results from IQVIA™ Disease Analyzer Germany." European Journal of Clinical Pharmacology, vol. 79, no. 12, 2023, pp. 1827-1836. https://doi.org/10.1007/s00228-023-03439-3.
27) Emery Pharma. "Countdown to Compliance: The August 2025 Deadline for NDSRI Testing Looms Over Pharmaceutical Industry." Emery Pharma, https://emerypharma.com/blog/countdown-to-compliance-the-august-2025-deadline-for-ndsri-testing-looms-over-pharmaceutical-industry/. Accessed 17 Feb. 2025.
28) Pawar, Sagar. "6 Steps to Reduce Nitrosamines Impurities in Pharma Industry." LinkedIn, 5 Aug. 2024, https://www.linkedin.com/pulse/6-steps-reduce-nitrosamines-impurities-pharma-industry-sagar-pawar-xld0e. Accessed 17 Feb. 2025.
29) "Quantitative Analysis of Nitrosamine Impurities." Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, [www.sigmaaldrich.com/IN/en/technical-documents/technical-article/pharmaceutical-and-biopharmaceutical-manufacturing/small-molecules-analysis-quality-control/quantitative-analysis-of-nitrosamine-impurities] Accessed 21 Jan. 2025.
30) Karishma P. Fuse and Vinod H. Jadhav. "Insight into Analytical Techniques for the Detection of Nitrosamine Impurities: A Review." Asian Journal of Pharmaceutical Analysis, vol. 13, no. 1, 2023, pp. 30-34. doi:10.52711/2231-5675.2023.00005.
31) Attaluri, Venkata Ranga Rao. “Safeguarding Purity Under Pressure: Detecting Nitrosamine Contamination.” European Pharmaceutical Review, 23 Apr. 2024.
32) Application Note: Nitrosamines in Drug Product by HRAM-LCMS." European Pharmaceutical Review, 2024, www.europeanpharmaceuticalreview.com/whitepaper/120976/application-note-nitrosamines-in-drug-product-by-hram-lcms/. Accessed 16 Feb. 2025.
33) Maurer, Hans H. "Multi-Analyte Procedures for Screening for and Quantification of Drugs in Blood, Plasma, or Serum by Liquid Chromatography-Single Stage or Tandem Mass Spectrometry (LC-MS or LC-MS/MS) Relevant to Clinical and Forensic Toxicology." Journal of Analytical Toxicology, vol. 29, no. 1, 2005, pp. 30–42.
34) Timms JF, Cutillas PR. Overview of quantitative LC-MS techniques for proteomics and activitomics. Methods Mol Biol. 2010;658:19-45. doi: 10.1007/978-1-60761-780-8_2. PMID: 20839096.
35) Manchuri, Krishna Moorthy, et al. “Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.” Chemical Research in Toxicology, vol. 37, no. 9, 2024, pp. 1456-1483.
36) Kim, Min-Jeong, et al. "Comparison of EI-GC-MS/MS, APCI-LC-MS/MS, and ESI-LC-MS/MS for the Simultaneous Analysis of Nine Nitrosamines Eluted from Synthetic Resins into Artificial Saliva and Health Risk Assessment." PubMed, 23 Sept. 2021, https://pubmed.ncbi.nlm.nih.gov/34678926/. Accessed 17 Feb. 2025.
37) Kamaris, Georgios, et al. "A Pre-Column Derivatization Method for the HPLC-FLD Determination of Dimethyl and Diethyl Amine in Pharmaceuticals." Molecules, vol. 29, no. 23, 2024, p. 5535. https://doi.org/10.3390/molecules29235535.
38) Boczar, Dariusz, Elżbieta Wyszomirska, Beata Zabrzewska, Anna Chyła, and Katarzyna Michalska. "Development and Validation of a Method for the Semi-Quantitative Determination of N-Nitrosamines in Active Pharmaceutical Ingredient Enalapril Maleate by Means of Derivatisation and Detection by HPLC with Fluorimetric Detector." Molecules, vol. 29, no. 5, 2024, pp. 1234-1245. https://doi.org/10.3390/molecules29051234.
39) Manchuri, Krishna Moorthy, et al. “Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.” Chemical Research in Toxicology, vol. 37, no. 9, 2024, pp. 1456-1483
40) Nori, L. P., Rehana, S., Penamacha, A., Somalanka, B. M., & Raju, K. V. (2023). A Study of Nitrosamine Impurities and Regulations Governing their Presence in Drug Products. International Journal of Pharmaceutical Investigation, 13(4), 680–687. https://doi.org/10.5530/ijpi.13.4.085
41) "Workflows for Quality Risk Management of Nitrosamine Risks in Medicines." EFPIA, Aug. 2022, www.efpia.eu/media/676632/efpia-nitrosamines-quality-risk-management-workflows-sep-2022.pdf. Accessed 16 Feb. 2025

42) Galande, Amol, et al. "A Checklist For Risk Assessment Of Nitrosamine Impurities In Oral Solid Dose Drugs." Outsourced Pharma, 2021.
43) Berardi, Alberto, Pauline H.M. Janssen, Bastiaan H.J. Dickhoff, and Sander van Gessel. "Nitrosamines Risk Mitigation: The Critical Role of Excipients and Supplier Qualification." DFE Pharma, Goch, Germany, 2025. https://dfepharma.com/media/44hnkq2p/nitrosamineswhite-paper.pdf.
44) European Medicines Agency. Assessment Report: Nitrosamine Impurities in Human Medicinal Products. EMA/369136/2020, 25 June 2020, www.ema.europa.eu/en/documents/report/nitrosamine-impurities-human-medicinal-products-assessment-report_en.pdf.
45) Shakleya D, Alayoubi A, Brown D, Mokbel A, Abrigo N, Mohammad A, Wang J, Li D, Shaklah M, Alsharif FM, Desai S, Essandoh M, Faustino PJ, Ashraf M, O' Connor T, Vera M, Raw A, Sayeed VA, Keire D. Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets. Int J Pharm. 2024 Dec 5;666:124832. doi: 10.1016/j.ijpharm.2024.124832. Epub 2024 Oct 14. PMID: 39414182.
46) "Update of the Requirements for Dealing with Nitrosamine Impurities in Medicinal Products." Swissmedic, 20 Sept. 2023, www.swissmedic.ch/dam/swissmedic/de/dokumente/stab/networking/praesentations folien-info-anlass-umgang-nitrosamin-verunreinigungen-in-am.pdf.download.pdf/Swissmedic_Online%20Information%20Event_Nitrosamines_20.09.2023_Presentation.pdf. Accessed 16 Feb. 2025.
47) Conclusion of Report: Paracetamol Is Safe to Use." Netherlands Medicines Authority MEB, 26 Aug. 2020, english.cbg-meb.nl/latest/news/2020/08/26/conclusion-of-report-paracetamol-is-safe-to-use. Accessed 16 Feb. 2025.
48) Arthur C. and Amandine B. "(Total) Recall: Chronicle of an Announced War Against Nitrosamines." Avertim, 22 Nov. 2021, www.avertim.com/en/news/total-recall-chronicle-announced-war-against-nitrosamines. Accessed 16 Feb. 2025.
49) "Nitrosamine Impurities: Assessing Concerns through Case Studies." Asian Journal of Chemistry, vol. 35, no. 4, 2023, asianpubs.org/index.php/ajchem/article/view/35_4_2. Accessed 16 Feb. 2025.
50) Aloka Srinivasan. "What Does the FDA's Recent Update of the Nitrosamine Guidance Convey?" Pharmaceutical Technology, 23 Oct. 2024, www.pharmtech.com/view/what-does-the-fda-s-recent-update-of-the-nitrosamine-guidance-convey-. Accessed 16 Feb. 2025.